Pharmaceutical - Japan

Filter

Current filters:

Japan

Popular Filters

1 to 25 of 63 results

ADHD treatment market set to reach $9.9 billion by 2020

ADHD treatment market set to reach $9.9 billion by 2020

22-08-2014

The attention-deficit hyperactivity disorder (ADHD) therapeutics market value will rise from $6.9 billion…

ADHDEuropeJapanNeurologicalPharmaceuticalPsychiatryUSA

Eisai teams up with Zeria on proton pump inhibitor license agreement

Eisai teams up with Zeria on proton pump inhibitor license agreement

18-08-2014

Japanese drug major Eisai has collaborated with fellow Japanese company Zeria Pharmaceutical to conclude…

EisaiGastro-intestinalsJapanLicensingPharmaceuticalProton pump inhibitorsZeria Pharmaceuticals

Brazil and Japan sign health cooperation agreement

Brazil and Japan sign health cooperation agreement

11-08-2014

Brazil's Ministry of Health has signed a memorandum of global cooperation with the government of Japan,…

BrazilHealthcareJapanPharmaceuticalUnited Nations Development Group

MS market to reach $20 billion in 2023 boosted by five new therapies

MS market to reach $20 billion in 2023 boosted by five new therapies

08-08-2014

The forecast launch of five immunomodulatory therapies for relapsing forms of multiple sclerosis will…

CNS DiseasesEuropeImmunosuppressantsJapanMarkets & MarketingMSPharmaceuticalUSA

Kyowa Hakko Kirin subsidiary ProStrakan acquires Archimedes

Kyowa Hakko Kirin subsidiary ProStrakan acquires Archimedes

06-08-2014

Japanese drugmaker Kyowa Hakko Kirin subsidiary, the Scotland-based ProStrakan, has acquired Archimedes…

ArchimedesArchimedes PharmaFentanylJapanKyowa Hakko KirinMergers & AcquisitionsNovo A/SNovo NordiskPharmaceuticalProStrakan

Taiho Pharma drops orantinib Ph III trial

Taiho Pharma drops orantinib Ph III trial

04-08-2014

Japanese drugmaker Taiho Pharmaceutical says it is terminating a Phase III clinical trial (ORIENTAL trial)…

Hepatocellular carcinomaHepatologyJapanOncologyorantinibPharmaceuticalResearchS-1TACETaiho PharmaceuticalTSU-68

Eisai's Fycompa launches in Belgium for partial-onset seizures

Eisai's Fycompa launches in Belgium for partial-onset seizures

04-08-2014

Fycompa (perampanel), an epilepsy drug developed by Japanese dug major Eisai, launches today in Belgium.

BelgiumCentral nervous systemEisaiEpilepsyFycompaJapanNeurologicalPharmaceuticalRegulation

Kyowa Hakko Kirin files for KW-3357 approval in Japan

Kyowa Hakko Kirin files for KW-3357 approval in Japan

01-08-2014

Japanese drugmaker Kyowa Hakko Kirin has filed an application for marketing approval with the Ministry…

HematologyJapanKW-3357Kyowa Hakko KirinPharmaceuticalRare diseasesRegulationThrombus

AstraZeneca and Kyowa Hakko Kirin sign immunotherapy research deal

AstraZeneca and Kyowa Hakko Kirin sign immunotherapy research deal

30-07-2014

Anglo-Swedish pharma major AstraZeneca today announced that it has entered into a clinical study collaboration…

AstraZenecaBriggs MorrisonImmunologyJapanKyowa Hakko KirinOncologyPharmaceuticalResearchUK

Bristol-Myers and Ono Pharma enter Asia oncology accord

Bristol-Myers and Ono Pharma enter Asia oncology accord

24-07-2014

US pharma major Bristol-Myers Squibb and Japan’s Ono Pharmaceutical have signed a strategic collaboration…

Asia-PacificBristol-Myers SquibbJapanLicensinglirilumabMelanomaOncologyOno PharmaceuticalOpdivoPharmaceuticalurelumabYervoy

Drug-treated hepatitis C population to more than double by 2016

Drug-treated hepatitis C population to more than double by 2016

16-07-2014

The hepatitis C virus population is already large, with 2 million diagnosed, chronically infected cases…

Anti-viralsCytokinesDaklinzaDecision Resources GroupEuropeHepatitis CInterferonJapanMarkets & MarketingPharmaceuticalUSA

Astellas submits sNDA for Irribow/Irribow OD in Japan

Astellas submits sNDA for Irribow/Irribow OD in Japan

14-07-2014

Japanese drug major Astellas Pharma has submitted a supplemental New Drug Application for the indication…

Astellas PharmaGastro-intestinalsIrribowJapanPharmaceuticalRegulation

Bristol-Myers hepatitis C treatment Daklinza+Sunvepra OKed in Japan

Bristol-Myers hepatitis C treatment Daklinza+Sunvepra OKed in Japan

07-07-2014

The Japanese Ministry of Health, Labor and Welfare has approved Daklinza (daclatasvir), a potent, pan-genotypic…

Anti-viralsBristol-Myers SquibbDaklinzaDaklinza+SunvepraJapanPharmaceuticalRegulationSunvepra

Japan marketing approval for Canaglu; vaccine license for Daiichi Sankyo

Japan marketing approval for Canaglu; vaccine license for Daiichi Sankyo

04-07-2014

Japanese drug major Mitsubishi Tanabe Pharma has received approval to manufacture and market the SGLT2…

canagliflozinCanagluDaiichi SankyoDiabetesJapanMitsubishi TanabePharmaceuticalRegulationSanofi PasteurVaccines

Japan first to approve Roche’s lung cancer drug alectinib

Japan first to approve Roche’s lung cancer drug alectinib

04-07-2014

The Japanese Ministry of Health, Labor and Welfare has approved Swiss pharma major Roche’s alectinib…

alectinibJapanOncologyPharmaceuticalRegulationRoche

1 to 25 of 63 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top